Novel Latency Reversal Agents for HIV-1 Cure.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 29099677.
- Also identified by DOI 10.1146/annurev-med-052716-031710 and PMC identifier 5892446.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Antiretroviral therapy (ART) has rendered HIV-1 infection a treatable illness; however, ART is not curative owing to the persistence of replication-competent, latent proviruses in long-lived resting T cells. Strategies that target these latently infected cells and allow immune recognition and clearance of this reservoir will be necessary to eradicate HIV-1 in infected individuals. This review describes current pharmacologic approaches to reactivate the latent reservoir so that infected cells can be recognized and targeted, with the ultimate goal of achieving an HIV-1 cure.
Medical subject headings
- HIV Infections
- HIV-1
- T-Lymphocytes
- Virus Activation
- Virus Latency